Notice: This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CYTX vs. AGEN, RGLS, DOMH, FBIO, CRIS, BOLT, SABS, MTEM, AMGN, and GILDShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Agenus (AGEN), Regulus Therapeutics (RGLS), Dominari (DOMH), Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Agenus Regulus Therapeutics Dominari Fortress Biotech Curis Bolt Biotherapeutics SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Agenus (NASDAQ:AGEN) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Which has more volatility & risk, AGEN or CYTX? Agenus has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Does the MarketBeat Community believe in AGEN or CYTX? Agenus received 25 more outperform votes than Cytori Therapeutics when rated by MarketBeat users. However, 73.67% of users gave Cytori Therapeutics an outperform vote while only 69.19% of users gave Agenus an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.19% Underperform Votes20830.81% Cytori TherapeuticsOutperform Votes44273.67% Underperform Votes15826.33% Which has preferable earnings & valuation, AGEN or CYTX? Cytori Therapeutics has lower revenue, but higher earnings than Agenus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$156.31M0.50-$245.76M-$11.24-0.30Cytori Therapeutics$3.67M7.25-$12.63MN/AN/A Do insiders and institutionals hold more shares of AGEN or CYTX? 61.5% of Agenus shares are owned by institutional investors. Comparatively, 2.6% of Cytori Therapeutics shares are owned by institutional investors. 4.6% of Agenus shares are owned by insiders. Comparatively, 0.7% of Cytori Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor AGEN or CYTX? In the previous week, Agenus' average media sentiment score of 1.00 beat Cytori Therapeutics' score of 0.00 indicating that Agenus is being referred to more favorably in the media. Company Overall Sentiment Agenus Positive Cytori Therapeutics Neutral Is AGEN or CYTX more profitable? Agenus has a net margin of -145.89% compared to Cytori Therapeutics' net margin of -242.60%. Agenus' return on equity of 0.00% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% Cytori Therapeutics -242.60%-272.70%-56.23% Do analysts prefer AGEN or CYTX? Agenus currently has a consensus price target of $10.00, indicating a potential upside of 201.20%. Given Agenus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agenus is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAgenus beats Cytori Therapeutics on 10 of the 15 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.59M$4.71B$5.84B$9.14BDividend YieldN/A39.90%4.75%3.85%P/E RatioN/A30.1926.7419.18Price / Sales7.2555.31435.4670.76Price / CashN/A51.1038.0134.83Price / Book3.436.577.644.62Net Income-$12.63M$90.91M$3.19B$246.06M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$1.20+0.0%N/A-40.3%$26.59M$3.67M0.0037AGENAgenus4.0657 of 5 stars$3.51+0.3%$10.00+184.9%-74.8%$82.35M$156.31M-0.31440RGLSRegulus Therapeutics2.5347 of 5 stars$1.21flat$10.80+792.6%-13.2%$79.26MN/A-1.1330DOMHDominari0.5916 of 5 stars$11.94-8.2%N/A+305.9%$75.70M$2.04M-3.094Gap UpHigh Trading VolumeFBIOFortress Biotech1.8863 of 5 stars$1.71-2.8%$13.67+699.2%-6.4%$47.20M$84.51M-0.56170CRISCuris2.7966 of 5 stars$3.22+2.5%$23.00+614.3%-69.9%$27.27M$10.02M-0.4160Gap UpBOLTBolt Biotherapeutics3.148 of 5 stars$0.50+2.8%$3.50+597.5%-56.8%$19.20M$7.88M-0.2990Gap DownSABSSAB Biotherapeutics2.3803 of 5 stars$1.98+13.1%$12.40+526.3%-64.8%$18.27M$2.24M0.00140MTEMMolecular TemplatesN/A$0.00+66.7%N/A-100.0%$3,000.00$57.31M0.00260Gap UpAMGNAmgen4.4634 of 5 stars$291.16-2.0%$314.09+7.9%+6.9%$156.51B$33.42B38.5626,700Insider TradePositive NewsGILDGilead Sciences4.7795 of 5 stars$104.08-1.8%$101.33-2.6%+50.2%$129.71B$27.12B1,156.4418,000Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive News Related Companies and Tools Related Companies AGEN Competitors RGLS Competitors DOMH Competitors FBIO Competitors CRIS Competitors BOLT Competitors SABS Competitors MTEM Competitors AMGN Competitors GILD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
